.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,663,687

« Back to Dashboard

Details for Patent: 8,663,687

Title:Film compositions for delivery of actives
Abstract: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain at least one active agent, which may be administered to a user topically, transmucosally, vaginally, ocularly, aurally, nasally, transdermally or orally.
Inventor(s): Myers; Garry L. (Kingsport, TN), Fuisz; Richard C. (Beverly Hills, CA)
Assignee: MonoSol Rx, LLC (Warren, NJ)
Filing Date:May 13, 2010
Application Number:12/779,316
Claims:1. A self-supporting film composition comprising: (i) a water soluble polymer composition comprising polyethylene oxide and a saccharide-based polymer; and (ii) a topical agent; wherein said topical agent is in the form of a small-scale particle selected from the group consisting of at least one type of nanoparticle, at least one type of micelle, at least one type of microdroplet, at least one type of microparticle, at least one type of liquid crystal, and combinations thereof, and wherein said small-scale particle of at least one agent is uniformly distributed in the film composition and uniformity is measured by equally sized individual unit doses which do not vary by more than 10% by weight of said small-scale particle of at least one agent from a desired dose.

2. The composition of claim 1, wherein said topical agent is in the form of at least one type of liquid crystal.

3. The composition of claim 1, wherein said topical agent is in the form of at least one type of micelle.

4. The composition of claim 1, wherein said topical agent is bound to at least one ligand.

5. A dosage composition comprising: a. A self-supporting film comprising: i. At least one polymer; and ii. At least one agent; wherein said at least one agent is in the form of a small-scale particle selected from the group consisting of at least one type of nanoparticle, at least one type of micelle, at least one type of microdroplet, at least one type of microparticle, at least one type of liquid crystal, and combinations thereof, and wherein said small-scale particle of at least one agent is uniformly distributed in the dosage composition and uniformity is measured by equally sized individual unit doses which do not vary by more than 10% by weight of said small-scale particle of at least one agent from a desired dose.

6. The composition of claim 5, wherein said agent is in the form of at least one type of liquid crystal.

7. The composition of claim 5, wherein said agent is in the form of at least one type of micelle.

8. The composition of claim 5, wherein said agent is bound to at least one ligand.

9. A method of forming a self-supporting film dosage composition, comprising the steps of: a. Providing a polymeric matrix; b. Forming a small-scale form of at least one agent; c. Dispersing said small-scale form of at least one agent throughout said polymeric matrix; d. Drying said polymeric matrix so as to form a self-supporting film dosage composition comprising said small-scale form of at least one agent; wherein said small-scale form of at least one agent is selected from the group consisting of at least one type of nanoparticle, at least one type of microparticle, at least one type of microdroplet, at least one type of micelle, at least one type of liquid crystal, and combinations thereof, and wherein said small-scale form of at least one agent is uniformly distributed in the film dosage composition and uniformity subsequent to dispersing and drying is measured by equally sized individual unit doses which do not vary by more than 10% by weight of said small-scale form of at least one agent from a desired dose.

10. The method of claim 9, wherein said agent is in the form of at least one type of microdroplet.

11. The method of claim 9, wherein said agent is in the form of at least one type of micelle.

12. The method of claim 9, wherein said small-scale form of at least one agent is formed through emulsion processing.

13. The method of claim 9, wherein said small-scale form of at least one agent is formed through milling.

14. The method of claim 9, wherein said small-scale form of at least one agent is formed through processing via a microfluidics pumping apparatus.

15. The method of claim 9, wherein said small-scale form of at least one agent is bound to at least one ligand.

16. The method of claim 9, wherein said step of drying said polymeric matrix comprises heating said polymeric matrix so as to rapidly form a visco-elastic mass to maintain a uniform distribution of said agent by locking-in or preventing migration of said agent within said visco-elastic mass within the first 10 minutes or less to maintain a uniform distribution of said agent by locking-in or preventing migration of said agent within said visco-elastic mass.

17. The method of claim 16, wherein said polymeric matrix containing said agent varies no more than 10% by weight of said agent throughout said polymeric matrix.

18. The method of claim 16, wherein said step of drying said polymeric matrix further comprises further drying said visco-elastic mass so as to provide a self-supporting film dosage composition having a solvent content of 10% or less.

19. The method of claim 16, wherein said step of forming a visco-elastic mass occurs within the first 0.5 to about 10 minutes of heating to maintain a uniform distribution of said agent by locking-in or preventing migration of said agent within said visco-elastic mass.

20. The method of claim 19, wherein said polymeric matrix containing said agent varies no more than 10% by weight of said agent throughout said polymeric matrix.

21. The method of claim 19, wherein said step of drying said polymeric matrix further comprises further drying said visco-elastic mass so as to provide a self-supporting film dosage composition having a solvent content of 10% or less.

22. The method of claim 9, wherein said small-scale form of at least one agent is formed through processing via a high shear apparatus.

23. The method of claim 9, wherein said small-scale form of said agent is in the form of at least one liquid crystal.

24. A method of forming a self-supporting film dosage composition, comprising the steps of: a. Providing a polymeric matrix; b. Forming a small-scale form of at least one agent; c. Applying said small-scale form of at least one agent to said polymeric matrix via deposition; and d. Drying said polymeric matrix so as to form a self-supporting film dosage composition comprising said small-scale form of at least one agent, wherein said small-scale form of at least one agent is selected from the group consisting of at least one type of nanoparticle, at least one type of micelle, at least one type of microdroplet, at least one type of microparticle, at least one type of liquid crystal, and combinations thereof, and wherein said small-scale form of at least one agent is uniformly distributed on the film dosage composition and uniformity subsequent to applying and drying is measured by equally sized individual unit doses which do not vary by more than 10% by weight of said small-scale form of at least one agent from a desired dose.

25. The method of claim 24, wherein said agent is in the form of at least one type of microdroplet.

26. The method of claim 24, wherein said agent is in the form of at least one type of micelle.

27. The method of claim 24, wherein said small-scale form of at least one agent is formed through emulsion processing.

28. The method of claim 24, wherein said small-scale form of at least one agent is formed through milling.

29. The method of claim 24, wherein said small-scale form of at least one agent is formed through processing via a microfluidics pumping apparatus.

30. The method of claim 24, wherein said small-scale form of at least one agent is bound to at least one ligand.

31. The method of claim 24, wherein said small-scale form of at least one agent is formed through processing via a high shear apparatus.

32. The method of claim 24, wherein said small-scale form of said agent is in the form of at least one liquid crystal.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc